BioNTech (NASDAQ:BNTX) Trading 7.4% Higher – Here’s What Happened

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) rose 7.4% during trading on Friday . The stock traded as high as $120.33 and last traded at $119.05. Approximately 1,254,472 shares changed hands during trading, an increase of 16% from the average daily volume of 1,084,099 shares. The stock had previously closed at $110.89.

Key Headlines Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech shares increased alongside Moderna as the mRNA trade rebounded for a third session. The move reflects renewed investor interest in mRNA-based cancer vaccines after Moderna’s trial news, rather than a new BioNTech announcement. Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
• Positive Sentiment: BioNTech highlighted upcoming late-stage lung-cancer data at the 2026 World Conference on Lung Cancer, including first global data for the pumitamig/elfetabart drozuntecan combination. The planned presentations support the company’s pipeline narrative and could provide future catalysts, although the data are not yet available. BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data
• Neutral Sentiment: BioNTech became the focus of unusually high options activity, indicating elevated speculative positioning and expectations for continued volatility. Options volume alone does not establish the direction of the stock. BioNTech Target of Unusually High Options Trading
• Negative Sentiment: The stock previously pulled back as Moderna gave back part of its sharp cancer-vaccine rally, demonstrating that BNTX remains highly sensitive to peer-company data and shifting mRNA-sector sentiment. Analysts also cautioned that the rally driven by Moderna’s results may fade without BioNTech-specific evidence. BioNTech’s Rally on Moderna Trial Win Likely to Fade

Analyst Upgrades and Downgrades

Several analysts recently weighed in on BNTX shares. Wells Fargo & Company lowered their price objective on BioNTech from $150.00 to $140.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. HC Wainwright reaffirmed a “buy” rating and set a $130.00 target price on shares of BioNTech in a report on Monday, April 27th. Canaccord Genuity Group set a $142.00 target price on BioNTech in a research report on Wednesday, August 5th. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Citigroup lowered their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $127.81.

BioNTech Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company’s fifty day moving average price is $92.91 and its 200 day moving average price is $95.64. The firm has a market capitalization of $29.32 billion, a price-to-earnings ratio of -14.81 and a beta of 1.27.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period last year, the company posted ($1.60) earnings per share. Equities research analysts expect that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

BioNTech declared that its board has initiated a share buyback plan on Thursday, May 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On BioNTech

Large investors have recently added to or reduced their stakes in the stock. Flossbach Von Storch SE acquired a new position in shares of BioNTech during the second quarter valued at $207,142,000. BNP Paribas Financial Markets grew its holdings in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares during the period. Bank of America Corp DE grew its stake in shares of BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after purchasing an additional 166,432 shares during the last quarter. GSK plc acquired a new position in BioNTech in the fourth quarter worth approximately $84,711,000. Finally, First Trust Advisors LP grew its holdings in shares of BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after acquiring an additional 451,124 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.